{
    "nct_id": "NCT04505839",
    "official_title": "First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors",
    "inclusion_criteria": "* Advanced-stage solid tumor (metastatic or locally advanced and unresectable) with histologically confirmed diagnosis of CRC, NSCLC, GC, RCC, or HCC\n* Measurable lesion(s) according to RECIST 1.1 criteria\n* Performance status of â‰¤ 2 on the Eastern Cooperative Oncology Group (ECOG) scale.\n* Ability to swallow capsules\n* Received last chemotherapy, biologic, or investigational therapy at least 4 weeks prior to first dosing of study treatment\n* Has received or is intolerant to all standard of care treatment options with known clinical benefit\n* Life expectancy of more than 3 months\n* Adequate hematological, hepatic and renal function\n* For women of childbearing potential, a negative serum pregnancy test performed within 7 days prior to start of treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry\n* Major surgery within the last 28 days prior to the first dose of investigational drug\n* Prior radiation therapy within 14 days prior to study Cycle 1 Day 1 and/or persistence of radiation-related adverse effects.\n* Concurrent treatment with any anticancer agent\n* Currently taking either strong CYP inhibitors or inducers\n* Known brain metastases, uncontrolled seizure disorder, or active neurologic disease\n* Significant cardiovascular impairment\n* Pregnant or nursing\n* Known HIV infection, active hepatitis C and/or hepatitis B infection\n* Known bleeding disorder or coagulopathy\n* Active drug or alcohol abuse or history of alcohol or drug abuse during the last two years.\n* Diagnosis of osteoporosis at the time of the screening\n* Any history of retinal pathology including diabetic retinopathy, macular degeneration, or other retinal degenerative disease",
    "miscellaneous_criteria": ""
}